Hanmi registered novel process patent for Paclitaxel in Japan.

Published: 2002-05-20 06:56:00

Updated: 2002-05-20 06:56:00

Hanmi pharmaceutical company announced on May 15 that a novel process patent for Paclitaxel, an anti-cancer drug, had been successfully registered in Japan, claiming that this process showed far higher yield with purity under a mild manufacturing condition compared to the existing process.

Han...

Fees

- Email service daily and homepage access.

$300 per month. ($3,240 per year)
5 Email holders per each company.
Anual contract base.

Latest News

Which are outstanding tetravalent vaccines even for the young?

Disease treated the most with clinical trial drugs is respiratory disorder like lung cancer

Who will be the next Pharmaceutical Safety Bureau Director?

Celltrion completes clinical trials for Remsima SC for European approval

Sales listed pharmas made in the first half of the year

TOP

BACK